Andrew E. Aplin, PhD

Contact Dr. Aplin

233 South 10th Street
BLSB 522
Philadelphia, PA 19107

(215) 503-7296
(215) 923-9248 fax

Most Recent Peer-reviewed Publications

  1. ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
  2. The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells
  3. In vivo E2F reporting reveals efficacious schedules of MEK1/2–CDK4/6 targeting and mTOR–s6 resistance mechanisms
  4. A preexisting rare PIK3CAe545ksubpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling
  5. Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma
  6. Novel therapeutic strategies and targets in advanced uveal melanoma
  7. CKS1 expression in melanocytic nevi and melanoma
  8. Response and resistance to paradox-breaking BRAF inhibitor in melanomas in vivo and Ex vivo
  9. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma
  10. “If you want to go far, go together”
  11. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis
  12. Inhibition of age-related therapy resistance in melanoma by rosiglitazone-mediated induction of klotho
  13. Dysregulated GPCR signaling and therapeutic options in uveal melanoma
  14. Co-Targeting HGF/cMET Signaling with MEK Inhibitors in metastatic uveal melanoma
  15. Running INTERFERONce on immunotherapy
  16. An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma
  17. Triple jeopardy for people with albinism
  18. The melanoma field with dendritic roots
  19. The state of melanoma: challenges and opportunities
  20. Targeting mutant NRAS signaling pathways in melanoma